Q-omics provides the consensus-scored VN1R76P profile across patient tissues and cancer cell-line models. VN1R76P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VN1R76P is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, VN1R76P RNA expression shows 9,520 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUAD, and GBM as cancer lineages where VN1R76P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VN1R76P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VN1R76P survival associations across molecular data types. VN1R76P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VN1R76P RNA expression–survival associations across cancer types. High VN1R76P expression shows unfavorable associations in KIRC, KIRP, CHOL, STAD and COAD, but favorable associations in LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for VN1R76P RNA expression.
This table summarizes VN1R76P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for VN1R76P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VN1R76P shows higher tumor expression in LUAD. The LUAD box plot shows higher VN1R76P RNA expression in tumor versus normal tissue (log2 FC = +0.044, t-test p = .025).
This table shows molecular features associated with VN1R76P in patient tissues and cancer cell lines. In patient samples, VN1R76P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
